Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life ...
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), hereafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced ...
Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen‘s regulatory application for the use of aducanumab in the treatment of Alzheimer’s disease. Alzheimer’s disease – the leading cause of ...
Popular Posts
